학술논문
Age and sex associate with outcome in older AML and high risk MDS patients treated with 10-day decitabine
Document Type
article
Author
Jacobien R. Hilberink; Isabelle A. van Zeventer; Dana A. Chitu; Thomas Pabst; Saskia K. Klein; Georg Stussi; Laimonas Griskevicius; Peter J. M. Valk; Jacqueline Cloos; Arjan A. van de Loosdrecht; Dimitri Breems; Danielle van Lammeren-Venema; Rinske Boersma; Mojca Jongen-Lavrencic; Martin Fehr; Mels Hoogendoorn; Markus G. Manz; Maaike Söhne; Rien van Marwijk Kooy; Dries Deeren; Marjolein W. M. van der Poel; Marie Cecile Legdeur; Lidwine Tick; Yves Chalandon; Emanuele Ammatuna; Sabine Blum; Bob Löwenberg; Gert J. Ossenkoppele; Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON); Swiss Group for Clinical Cancer Research (SAKK); Gerwin Huls
Source
Blood Cancer Journal, Vol 13, Iss 1, Pp 1-9 (2023)
Subject
Language
English
ISSN
2044-5385
Abstract
Abstract Treatment choice according to the individual conditions remains challenging, particularly in older patients with acute myeloid leukemia (AML) and high risk myelodysplastic syndrome (MDS). The impact of performance status, comorbidities, and physical functioning on survival is not well defined for patients treated with hypomethylating agents. Here we describe the impact of performance status (14% ECOG performance status 2), comorbidity (40% HCT-comorbidity index ≥ 2), and physical functioning (41% short physical performance battery 76 years was significantly associated with reduced OS (HR 1.58; p = 0.043) and female sex was associated with superior OS (HR 0.62; p = 0.06). We further compared the genetic profiles of these subgroups. This revealed comparable mutational profiles in patients younger and older than 76 years, but, interestingly, revealed significantly more prevalent mutated ASXL1, STAG2, and U2AF1 in male compared to female patients. In this cohort of older patients treated with decitabine age and sex, but not comorbidities, physical functioning or cytogenetic risk were associated with overall survival.